Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin for COVID-19 in Type 2 Diabetes
NCT04341935Phase 4Withdrawn
- Sponsor
- University of Miami
- Start
- Jun 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of linagliptin in coronavirus disease 2019 (COVID-19), type 2 diabetes mellitus (T2DM), sponsored by University of Miami. Planned start Jun 2021; status: withdrawn.
02
Drugs
linagliptin
03
Conditions
coronavirus disease 2019 (COVID-19)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04341935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04341935.